IL146729A0 - Screening methods for altering circadian rhythm proteins - Google Patents

Screening methods for altering circadian rhythm proteins

Info

Publication number
IL146729A0
IL146729A0 IL14672900A IL14672900A IL146729A0 IL 146729 A0 IL146729 A0 IL 146729A0 IL 14672900 A IL14672900 A IL 14672900A IL 14672900 A IL14672900 A IL 14672900A IL 146729 A0 IL146729 A0 IL 146729A0
Authority
IL
Israel
Prior art keywords
alter
ability
directed
screening methods
phosphorylation
Prior art date
Application number
IL14672900A
Other languages
English (en)
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of IL146729A0 publication Critical patent/IL146729A0/xx

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Peptides Or Proteins (AREA)
IL14672900A 1999-06-08 2000-06-07 Screening methods for altering circadian rhythm proteins IL146729A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32774599A 1999-06-08 1999-06-08
PCT/US2000/015633 WO2000075669A1 (en) 1999-06-08 2000-06-07 Screening methods for altering circadian rhythm proteins

Publications (1)

Publication Number Publication Date
IL146729A0 true IL146729A0 (en) 2002-07-25

Family

ID=23277866

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14672900A IL146729A0 (en) 1999-06-08 2000-06-07 Screening methods for altering circadian rhythm proteins
IL146729A IL146729A (en) 1999-06-08 2001-11-25 Sorting methods to change daily cycle proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL146729A IL146729A (en) 1999-06-08 2001-11-25 Sorting methods to change daily cycle proteins

Country Status (15)

Country Link
US (1) US6555328B1 (xx)
EP (1) EP1183541B1 (xx)
JP (1) JP4583682B2 (xx)
KR (1) KR100722176B1 (xx)
AT (1) ATE322016T1 (xx)
AU (1) AU767800B2 (xx)
BR (1) BR0011437A (xx)
CA (1) CA2375450C (xx)
DE (1) DE60026998T2 (xx)
IL (2) IL146729A0 (xx)
MX (1) MXPA01011417A (xx)
NO (3) NO330241B1 (xx)
NZ (1) NZ514603A (xx)
WO (1) WO2000075669A1 (xx)
ZA (1) ZA200108962B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436628B1 (en) 1998-06-19 2002-08-20 The Rockefeller University Methods of identifying an agent which modulates period and doubletime protein interaction
US6476188B1 (en) 1998-06-19 2002-11-05 The Rockefeller University Clock gene and methods of use thereof
CA2375450C (en) * 1999-06-08 2009-04-28 Aventis Pharmaceuticals Inc. Screening methods for altering circadian rhythm proteins
WO2001036618A2 (en) * 1999-11-18 2001-05-25 Mitsubishi Pharma Corporation Transgenic mammals into which a period 1 promoter that confers rhythmical expression has been introduced
GB0103110D0 (en) * 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
EP1358315A4 (en) * 2001-01-11 2005-11-16 Univ Utah Res Found IDENTIFYING AN ADVANCED SLEEP PHASE SYNDROME GENE IN PEOPLE
AU2003278333A1 (en) * 2002-10-25 2004-05-13 University Of Surrey Polymorphism in the per3 gene as a indicator in the diagnosis and treatment of circadian rhythm sleep disorders
EP1576133A2 (en) * 2002-11-27 2005-09-21 University of Utah Research Foundation Casein kinase i epsilon and casein kinase i delta and sleep in humans
JO2629B1 (en) * 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
JO2724B1 (en) * 2004-08-19 2013-09-15 افينتس فارماسوتيكالز انك 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
DK1791537T3 (da) * 2004-08-19 2010-03-01 Aventis Pharma Inc 3-arylthioindol-2-carboxamidderivater og analoger deraf som inhibitorer af casein-kinase
US20100028871A1 (en) * 2006-05-31 2010-02-04 National Institute Of Radiological Sciences Light-inducible and rhythmically expressed genes and method for screening substances that affect an internal clock system
ES2425179T3 (es) * 2006-10-25 2013-10-11 The Rockefeller University Métodos para el tratamiento de trastornos relacionados con beta-amiloide y composiciones para los mismos
FR2918986B1 (fr) 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
CN105744948B (zh) * 2013-10-14 2020-03-24 南京大学 进食节律提前综合征的识别方法及其应用
KR101600144B1 (ko) * 2013-12-20 2016-03-04 서울대학교산학협력단 일주기 리듬 수면장애 및 시차 부적응에 대한 예방 또는 치료제 스크리닝 방법
CA2935985A1 (en) 2014-01-09 2015-07-16 Intra-Cellular Therapies, Inc. Organic compounds
WO2017083835A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York Inhibition of tor complex 2 increases immunity against bacterial infection
WO2023129377A1 (en) * 2022-01-03 2023-07-06 The Johns Hopkins University Methods and materials for treating heart attack

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1157137A (ja) * 1997-08-28 1999-03-02 Sanyo Bussan Kk 遊技機用特別図柄表示装置
KR100246893B1 (ko) * 1997-12-29 2000-05-01 윤종용 전자렌지용 도어
WO1999057137A1 (en) * 1998-05-07 1999-11-11 The President & Fellows Of Harvard College Compositions and methods involving regulation of mammalian circadian rhythms
CA2375450C (en) * 1999-06-08 2009-04-28 Aventis Pharmaceuticals Inc. Screening methods for altering circadian rhythm proteins

Also Published As

Publication number Publication date
NO20100431L (no) 2002-02-05
MXPA01011417A (es) 2002-06-04
JP4583682B2 (ja) 2010-11-17
NO330241B1 (no) 2011-03-14
IL146729A (en) 2007-06-17
DE60026998D1 (de) 2006-05-18
EP1183541A1 (en) 2002-03-06
US6555328B1 (en) 2003-04-29
ATE322016T1 (de) 2006-04-15
CA2375450C (en) 2009-04-28
CA2375450A1 (en) 2000-12-14
AU767800B2 (en) 2003-11-27
BR0011437A (pt) 2002-03-05
NZ514603A (en) 2003-10-31
NO20100430L (no) 2002-02-05
NO20015972D0 (no) 2001-12-06
KR100722176B1 (ko) 2007-05-29
AU5468900A (en) 2000-12-28
KR20020033101A (ko) 2002-05-04
EP1183541B1 (en) 2006-03-29
WO2000075669A1 (en) 2000-12-14
JP2003501074A (ja) 2003-01-14
DE60026998T2 (de) 2007-04-05
ZA200108962B (en) 2003-01-30
NO20015972L (no) 2002-02-05

Similar Documents

Publication Publication Date Title
IL146729A0 (en) Screening methods for altering circadian rhythm proteins
EA200100589A1 (ru) Азабициклоалканы как модуляторы ccr5
EA200500856A1 (ru) Новые химические соединения
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
EA200100588A1 (ru) Пиперидины как модуляторы ccr5
CY1105836T1 (el) 12, 13-τροποποιημενα παραγωγα εποθιλονης
ATE269303T1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
DE69626660T2 (de) 2-alkylpyrrolidine
EA200001244A1 (ru) Комбинационная терапия для лечения биполярных расстройств
DE69739026D1 (de) Nitril-Hydratase, ihre Derivate und Verfahren zur Herstellung von Verbindungen
DE69941701D1 (de) Mutanten von flt3-l und ihre verwendungen
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE69903410D1 (de) Entkarbonisierung von gasen unter verwendung von zeolithischen adsorptionsmitteln
ATE218857T1 (de) Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen
DE69606837T2 (de) Gerät zur Überprüfung der Bestimmungen von klinischen Analysen
DE50011325D1 (de) Vorrichtung zur Erkennung der Kreislaufwirkungen von Extrasystolen
DE60028114D1 (de) Verfahren zur Analyse von ausgeatmetem Gas
DE59907526D1 (de) Verfahren zur Herstellung von 3-Cyano-3,5,5-trimethyl-cyclohexanon
NZ508444A (en) Using (R)-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3- pyridazinyl)phenyl]acetamide for treating heart failure
DE69734890D1 (de) Rdgb-proteine
ATE216386T1 (de) Kv2.1 antagonisten
WO1999050671A3 (en) Toso as a target for drug screening
DE69926996D1 (de) Verwendung von riluzol zur behandlung der retinalischemie
WO2003012103A3 (fr) Acides nucleiques codant de nouvelles proteines a boite f, leurs utilisations en diagnostic et en therapie
WO2003012102A3 (fr) Acides nucleiques codant des proteines a domaine hect

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed